title: Comparative in-vitro activity of LY146032 and eight other antibiotics against gram-positive bacteria isolated from children.
abstract: LY146032, a cyclic peptide antibiotic active against many Gram-positive bacteria, was compared to methicillin, vancomycin, clindamycin, cefuroxime and gentamicin against methicillin-resistant and methicillin-susceptible strains of Staphylococcus aureus and Staph. epidermidis. LY146032 was uniformly active against clinical isolates of staphylococci, inhibiting 90% of strains of Staph. aureus and Staph. epidermidis at a concentration of 0.5 mg/l. Vancomycin was slightly less active than LY146032 against Staph. aureus and Staph. epidermidis, inhibiting 90% of strains at concentrations of 1.0 and 2.0 mg/l, respectively. All other antibiotics tested were less active than LY146032 or vancomycin against staphylococci. LY146032 was compared to penicillin, ampicillin, vancomycin and chloramphenicol against strains of Streptococcus pneumoniae, group B streptococcus, group D streptococcus (enterococcus) and Listeria monocytogenes and was found to inhibit 90% of the strains at concentrations of 0.25, 1.0, 32.0 and 16.0 mg/l respectively. The combination of LY146032 and chloramphenicol was antagonistic in vitro for one strain each of Staph. aureus and group D streptococcus and showed indifference against other strains of Staph. aureus(2), Staph. epidermidis(2), group D streptococcus(1) and L. monocytogenes(2). LY146032 in combination with gentamicin showed indifference against the same bacteria. On the basis of its in-vitro activity, LY146032 appears to be a promising agent for the treatment of serious community- and hospital-acquired staphylococcal infections.
authors.affiliation: Department of Pediatrics, Texas Children's Hospital, Houston.
authors.forename: M W
authors.initials: MW
authors.lastname: Kline
authors.forename: E O
authors.initials: EO
authors.lastname: Mason
authors.forename: S L
authors.initials: SL
authors.lastname: Kaplan
authors.forename: L B
authors.initials: LB
authors.lastname: Lamberth
authors.forename: G S
authors.initials: GS
authors.lastname: Johnson
mesh_terms: D000900:Anti-Bacterial Agents / Q000494:pharmacology*; D002648:Child; D017576:Daptomycin; D006094:Gram-Positive Bacteria / Q000187:drug effects*; D006801:Humans; D008712:Methicillin / Q000494:pharmacology; D008826:Microbial Sensitivity Tests; D010403:Penicillin Resistance; D010455:Peptides / Q000494:pharmacology; D013210:Staphylococcus / Q000187:drug effects; D013291:Streptococcus / Q000187:drug effects
chemical_list: D000900:Anti-Bacterial Agents; D010455:Peptides; D017576:Daptomycin; D008712:Methicillin